-
Tigermed Announces Acquisition of Majority Stake in Shanghai Guanhe Pharmaceutical for CNY 140 Million
•
Tigermed (SHE: 300347, HKG: 3347) has announced its intention to acquire a 40.5650% stake in Shanghai Guanhe Pharmaceutical Co., Ltd (hereinafter referred to as “Guanhe Pharmaceutical”) from DiAn Diagnostics (SHE: 300244) and Suzhou Yingkai Xinyun Enterprise Management Consulting Co., Ltd (hereinafter referred to as “Suzhou Yingkai”, a subsidiary of DiAn…
-
Tigermed Partners with Purpose Africa to Boost Clinical Research and Healthcare Cooperation
•
Tigermed (SHE: 300347), a leading Contract Research Organization (CRO) in China, has entered into a strategic partnership with Purpose Africa, a Rwanda-based platform organization comprised of experts from African academia and industry. The collaboration aims to enhance China-Africa cooperation in the realms of clinical research and digital platform development, thereby…
-
Tigermed Partners with Beijing Government to Open North Headquarters, Expanding Collaboration in Biotech
•
Tigermed, a prominent Contract Research Organization (CRO) with a presence in both Shenzhen (SHE: 300347) and Hong Kong (HKG: 3347) stock exchanges, has forged a strategic partnership with the Beijing government. This collaboration is marked by the inauguration of the company’s North Headquarters in the capital city. Under this partnership,…
-
Tigermed Expands Asia Pacific Presence with Acquisition of Japanese CRO Medical Edge
•
Tigermed (SHE: 300347, HKG: 3347), a leading China-based Contract Research Organization (CRO), has announced the acquisition of Medical Edge Co., Ltd, a Japan-headquartered CRO. With this strategic move, Medical Edge will become a wholly-owned subsidiary of Tigermed, enhancing the company’s ability to provide high-quality mathematical statistics and electronic data solutions…
-
China’s Tigermed Taps Veeva Systems for Advanced Electronic Data Acquisition
•
Veeva Systems, a U.S.-based life science cloud software specialist, has entered into a partnership with China’s Contract Research Organization (CRO) Tigermed (SHE: 300347, HKG: 3347). This global collaboration is centered around the application of Veeva’s modern electronic data acquisition system, Vault EDC. The innovative digital solution is designed to enhance…
-
Hong Kong Government Partners with AstraZeneca, Tigermed, and Simcere to Boost Innovation
•
The government of the Hong Kong Special Administrative Region has entered into significant partnership agreements with AstraZeneca (AZ, NASDAQ: AZN), Tigermed (SHE: 300347), Simcere (HKG: 2096), and a total of 20 other companies. This initiative is set to generate cumulative investments of HKD 30 billion (approximately USD 3.83 billion) in…
-
Tigermed Establishes International Headquarters in Hong Kong to Accelerate Global Expansion
•
China-based Contract Research Organization (CRO) Tigermed (SHE: 300347, HKG: 3347) has announced the opening of its international headquarters in Hong Kong, signifying a significant milestone in the company’s efforts to globalize its operations and corporate development. The new international HQ is set to enhance Tigermed’s ability to coordinate and manage…
-
Teddy Clinical Research Lab Partners with Cerba Research for Global Services
•
China-based Teddy Clinical Research Laboratory Limited, a joint venture (JV) between Dian Diagnostics (SHE: 300244) and Tigermed (SHE: 300347, HKG: 3347), has struck a partnership with Belgium-headquartered Cerba Healthcare’s subsidiary Cerba Research. The two companies will set up a JV in Wuxi, Jiangsu Province, China, marking a significant expansion of…
-
Tigermed Completes Acquisition of Croatia-Based CRO Marti Farm
•
China-based Contract Research Organization (CRO) Tigermed (SHE: 300347, HKG: 3347) has announced the completion of its acquisition of Croatia-based Marti Farm. The deal, which strengthens Tigermed’s operational presence in Europe, adds local-level expertise to its global portfolio. Financial details of the transaction were not disclosed. Marti Farm: Services and CapabilitiesBased…
-
WuXi AppTec Faces Shareholder Divestment of Up to 3% Stake
•
China-based Contract Research Organization (CRO) WuXi AppTec Co., Ltd (SHA: 603259, HKG: 2359) has disclosed that a group of shareholders plans to divest up to 3% of their holdings in the company. This translates to the auctioning of up to 88.68 million A shares in blocks, representing RMB 9.12 billion…
